ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000D74

Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus

Identifieur interne : 000D74 ( PascalFrancis/Corpus ); précédent : 000D73; suivant : 000D75

Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus

Auteurs : A. F. Miranda ; M. A. Sutton ; R. J. Beninger ; K. Jhamandas ; R. J. Boegman

Source :

Neuroscience letters [ 0304-3940 ] ; 1999.

RBID : Pascal:99-0210506

Descripteurs français

Pascal (Inist)
- Lésion, Voie nigrostriatale, Comportement rotation, Neuroprotecteur, Parkinson maladie, Animal, Rat, Cynurénique acide.

English descriptors

KwdEn :
- Animal, Lesion, Neuroprotective agent, Nigrostriatal pathway, Parkinson disease, Rat, Rotation behavior.

Abstract

Endogenous excitotoxins have been implicated in degeneration of nigral dopaminergic neurons in Parkinson's disease. It may be possible to reduce neurodegeneration by blocking the effects of these endogenous agents. The present study shows that contralateral turning seen following quinolinic acid-induced lesions of the nigrostriatal dopaminergic pathway was reversed by a treatment that increased brain levels of kynurenic acid, an endogenous excitatory amino acid antagonist. The treatment consisted of nicotinylalanine (5.6 nmol/5 μl i.c.v.), an inhibitor of kynureninase and kynurenine hydroxylase plus the precursor kynurenine (450 mg/kg i.p.) plus probenencid (200 mg/kg i.p.), an inhibitor of organic acid transport. Thus, neuroprotection by increasing brain kynurenic acid in vivo may be useful in retarding cell loss in Parkinson's and other neurodegenerative diseases involving excitotoxicity.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0304-3940`
A02	`01`			`@0 NELED5`
A03		`1`		`@0 Neurosci. lett.`
A05				`@2 262`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus`
A11	`01`	`1`		`@1 MIRANDA (A. F.)`
A11	`02`	`1`		`@1 SUTTON (M. A.)`
A11	`03`	`1`		`@1 BENINGER (R. J.)`
A11	`04`	`1`		`@1 JHAMANDAS (K.)`
A11	`05`	`1`		`@1 BOEGMAN (R. J.)`
A14	`01`			`@1 Department of Pharmacology and Toxicology, Queen's University @2 Kingston, Ontario, K7L 3N6 @3 CAN @Z 1 aut. @Z 4 aut. @Z 5 aut.`
A14	`02`			`@1 Department of Psychology, Queen's University @2 Kingston, Ontario, K7L 3N6 @3 CAN @Z 2 aut. @Z 3 aut.`
A14	`03`			`@1 Department of Psychiatry, Queen's University @2 Kingston, Ontario, K7L 3N6 @3 CAN @Z 3 aut.`
A20				`@1 81-84`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17240 @5 354000074775170030`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 16 ref.`
A47	`01`	`1`		`@0 99-0210506`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neuroscience letters`
A66	`01`			`@0 IRL`
C01	`01`		`ENG`	@0 Endogenous excitotoxins have been implicated in degeneration of nigral dopaminergic neurons in Parkinson's disease. It may be possible to reduce neurodegeneration by blocking the effects of these endogenous agents. The present study shows that contralateral turning seen following quinolinic acid-induced lesions of the nigrostriatal dopaminergic pathway was reversed by a treatment that increased brain levels of kynurenic acid, an endogenous excitatory amino acid antagonist. The treatment consisted of nicotinylalanine (5.6 nmol/5 μl i.c.v.), an inhibitor of kynureninase and kynurenine hydroxylase plus the precursor kynurenine (450 mg/kg i.p.) plus probenencid (200 mg/kg i.p.), an inhibitor of organic acid transport. Thus, neuroprotection by increasing brain kynurenic acid in vivo may be useful in retarding cell loss in Parkinson's and other neurodegenerative diseases involving excitotoxicity.
C02	`01`	`X`		`@0 002B02B10`
C03	`01`	`X`	`FRE`	`@0 Lésion @5 01`
C03	`01`	`X`	`ENG`	`@0 Lesion @5 01`
C03	`01`	`X`	`SPA`	`@0 Lesión @5 01`
C03	`02`	`X`	`FRE`	`@0 Voie nigrostriatale @5 02`
C03	`02`	`X`	`ENG`	`@0 Nigrostriatal pathway @5 02`
C03	`02`	`X`	`SPA`	`@0 Vía nigroestriatal @5 02`
C03	`03`	`X`	`FRE`	`@0 Comportement rotation @5 03`
C03	`03`	`X`	`ENG`	`@0 Rotation behavior @5 03`
C03	`03`	`X`	`SPA`	`@0 Comportamiento rotación @5 03`
C03	`04`	`X`	`FRE`	`@0 Neuroprotecteur @5 04`
C03	`04`	`X`	`ENG`	`@0 Neuroprotective agent @5 04`
C03	`04`	`X`	`SPA`	`@0 Neuroprotector @5 04`
C03	`05`	`X`	`FRE`	`@0 Parkinson maladie @5 10`
C03	`05`	`X`	`ENG`	`@0 Parkinson disease @5 10`
C03	`05`	`X`	`SPA`	`@0 Parkinson enfermedad @5 10`
C03	`06`	`X`	`FRE`	`@0 Animal @5 11`
C03	`06`	`X`	`ENG`	`@0 Animal @5 11`
C03	`06`	`X`	`SPA`	`@0 Animal @5 11`
C03	`07`	`X`	`FRE`	`@0 Rat @5 54`
C03	`07`	`X`	`ENG`	`@0 Rat @5 54`
C03	`07`	`X`	`SPA`	`@0 Rata @5 54`
C03	`08`	`X`	`FRE`	`@0 Cynurénique acide @4 INC @5 81`
C07	`01`	`X`	`FRE`	`@0 Encéphale @5 23`
C07	`01`	`X`	`ENG`	`@0 Brain (vertebrata) @5 23`
C07	`01`	`X`	`SPA`	`@0 Encéfalo @5 23`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central @5 24`
C07	`02`	`X`	`ENG`	`@0 Central nervous system @5 24`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso central @5 24`
C07	`03`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`03`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`03`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`04`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`04`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`04`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`05`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`05`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`05`	`X`	`SPA`	`@0 Vertebrata @2 NS`
N21				`@1 130`

Format Inist (serveur)

NO :	PASCAL 99-0210506 INIST
ET :	Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus
AU :	MIRANDA (A. F.); SUTTON (M. A.); BENINGER (R. J.); JHAMANDAS (K.); BOEGMAN (R. J.)
AF :	Department of Pharmacology and Toxicology, Queen's University/Kingston, Ontario, K7L 3N6/Canada (1 aut., 4 aut., 5 aut.); Department of Psychology, Queen's University/Kingston, Ontario, K7L 3N6/Canada (2 aut., 3 aut.); Department of Psychiatry, Queen's University/Kingston, Ontario, K7L 3N6/Canada (3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neuroscience letters; ISSN 0304-3940; Coden NELED5; Irlande; Da. 1999; Vol. 262; No. 2; Pp. 81-84; Bibl. 16 ref.
LA :	Anglais
EA :	Endogenous excitotoxins have been implicated in degeneration of nigral dopaminergic neurons in Parkinson's disease. It may be possible to reduce neurodegeneration by blocking the effects of these endogenous agents. The present study shows that contralateral turning seen following quinolinic acid-induced lesions of the nigrostriatal dopaminergic pathway was reversed by a treatment that increased brain levels of kynurenic acid, an endogenous excitatory amino acid antagonist. The treatment consisted of nicotinylalanine (5.6 nmol/5 μl i.c.v.), an inhibitor of kynureninase and kynurenine hydroxylase plus the precursor kynurenine (450 mg/kg i.p.) plus probenencid (200 mg/kg i.p.), an inhibitor of organic acid transport. Thus, neuroprotection by increasing brain kynurenic acid in vivo may be useful in retarding cell loss in Parkinson's and other neurodegenerative diseases involving excitotoxicity.
CC :	002B02B10
FD :	Lésion; Voie nigrostriatale; Comportement rotation; Neuroprotecteur; Parkinson maladie; Animal; Rat; Cynurénique acide
FG :	Encéphale; Système nerveux central; Rodentia; Mammalia; Vertebrata
ED :	Lesion; Nigrostriatal pathway; Rotation behavior; Neuroprotective agent; Parkinson disease; Animal; Rat
EG :	Brain (vertebrata); Central nervous system; Rodentia; Mammalia; Vertebrata
SD :	Lesión; Vía nigroestriatal; Comportamiento rotación; Neuroprotector; Parkinson enfermedad; Animal; Rata
LO :	INIST-17240.354000074775170030
ID :	99-0210506

Links to Exploration step

Pascal:99-0210506

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus</title>
<author><name sortKey="Miranda, A F" sort="Miranda, A F" uniqKey="Miranda A" first="A. F." last="Miranda">A. F. Miranda</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pharmacology and Toxicology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sutton, M A" sort="Sutton, M A" uniqKey="Sutton M" first="M. A." last="Sutton">M. A. Sutton</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Beninger, R J" sort="Beninger, R J" uniqKey="Beninger R" first="R. J." last="Beninger">R. J. Beninger</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jhamandas, K" sort="Jhamandas, K" uniqKey="Jhamandas K" first="K." last="Jhamandas">K. Jhamandas</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pharmacology and Toxicology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Boegman, R J" sort="Boegman, R J" uniqKey="Boegman R" first="R. J." last="Boegman">R. J. Boegman</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pharmacology and Toxicology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0210506</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0210506 INIST</idno>
<idno type="RBID">Pascal:99-0210506</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D74</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus</title>
<author><name sortKey="Miranda, A F" sort="Miranda, A F" uniqKey="Miranda A" first="A. F." last="Miranda">A. F. Miranda</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pharmacology and Toxicology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sutton, M A" sort="Sutton, M A" uniqKey="Sutton M" first="M. A." last="Sutton">M. A. Sutton</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Beninger, R J" sort="Beninger, R J" uniqKey="Beninger R" first="R. J." last="Beninger">R. J. Beninger</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jhamandas, K" sort="Jhamandas, K" uniqKey="Jhamandas K" first="K." last="Jhamandas">K. Jhamandas</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pharmacology and Toxicology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Boegman, R J" sort="Boegman, R J" uniqKey="Boegman R" first="R. J." last="Boegman">R. J. Boegman</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pharmacology and Toxicology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroscience letters</title>
<title level="j" type="abbreviated">Neurosci. lett.</title>
<idno type="ISSN">0304-3940</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroscience letters</title>
<title level="j" type="abbreviated">Neurosci. lett.</title>
<idno type="ISSN">0304-3940</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Lesion</term>
<term>Neuroprotective agent</term>
<term>Nigrostriatal pathway</term>
<term>Parkinson disease</term>
<term>Rat</term>
<term>Rotation behavior</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lésion</term>
<term>Voie nigrostriatale</term>
<term>Comportement rotation</term>
<term>Neuroprotecteur</term>
<term>Parkinson maladie</term>
<term>Animal</term>
<term>Rat</term>
<term>Cynurénique acide</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Endogenous excitotoxins have been implicated in degeneration of nigral dopaminergic neurons in Parkinson's disease. It may be possible to reduce neurodegeneration by blocking the effects of these endogenous agents. The present study shows that contralateral turning seen following quinolinic acid-induced lesions of the nigrostriatal dopaminergic pathway was reversed by a treatment that increased brain levels of kynurenic acid, an endogenous excitatory amino acid antagonist. The treatment consisted of nicotinylalanine (5.6 nmol/5 μl i.c.v.), an inhibitor of kynureninase and kynurenine hydroxylase plus the precursor kynurenine (450 mg/kg i.p.) plus probenencid (200 mg/kg i.p.), an inhibitor of organic acid transport. Thus, neuroprotection by increasing brain kynurenic acid in vivo may be useful in retarding cell loss in Parkinson's and other neurodegenerative diseases involving excitotoxicity.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0304-3940</s0>
</fA01>
<fA02 i1="01"><s0>NELED5</s0>
</fA02>
<fA03 i2="1"><s0>Neurosci. lett.</s0>
</fA03>
<fA05><s2>262</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MIRANDA (A. F.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SUTTON (M. A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BENINGER (R. J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JHAMANDAS (K.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BOEGMAN (R. J.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Pharmacology and Toxicology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Psychology, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Psychiatry, Queen's University</s1>
<s2>Kingston, Ontario, K7L 3N6</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>81-84</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17240</s2>
<s5>354000074775170030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>16 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0210506</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuroscience letters</s0>
</fA64>
<fA66 i1="01"><s0>IRL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Endogenous excitotoxins have been implicated in degeneration of nigral dopaminergic neurons in Parkinson's disease. It may be possible to reduce neurodegeneration by blocking the effects of these endogenous agents. The present study shows that contralateral turning seen following quinolinic acid-induced lesions of the nigrostriatal dopaminergic pathway was reversed by a treatment that increased brain levels of kynurenic acid, an endogenous excitatory amino acid antagonist. The treatment consisted of nicotinylalanine (5.6 nmol/5 μl i.c.v.), an inhibitor of kynureninase and kynurenine hydroxylase plus the precursor kynurenine (450 mg/kg i.p.) plus probenencid (200 mg/kg i.p.), an inhibitor of organic acid transport. Thus, neuroprotection by increasing brain kynurenic acid in vivo may be useful in retarding cell loss in Parkinson's and other neurodegenerative diseases involving excitotoxicity.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lésion</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lesion</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Lesión</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Voie nigrostriatale</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nigrostriatal pathway</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vía nigroestriatal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Comportement rotation</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Rotation behavior</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Comportamiento rotación</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Neuroprotecteur</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Neuroprotective agent</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Neuroprotector</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Rat</s0>
<s5>54</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Rat</s0>
<s5>54</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Rata</s0>
<s5>54</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Cynurénique acide</s0>
<s4>INC</s4>
<s5>81</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>23</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>23</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>23</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>24</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>24</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>24</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>130</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0210506 INIST</NO>
<ET>Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus</ET>
<AU>MIRANDA (A. F.); SUTTON (M. A.); BENINGER (R. J.); JHAMANDAS (K.); BOEGMAN (R. J.)</AU>
<AF>Department of Pharmacology and Toxicology, Queen's University/Kingston, Ontario, K7L 3N6/Canada (1 aut., 4 aut., 5 aut.); Department of Psychology, Queen's University/Kingston, Ontario, K7L 3N6/Canada (2 aut., 3 aut.); Department of Psychiatry, Queen's University/Kingston, Ontario, K7L 3N6/Canada (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neuroscience letters; ISSN 0304-3940; Coden NELED5; Irlande; Da. 1999; Vol. 262; No. 2; Pp. 81-84; Bibl. 16 ref.</SO>
<LA>Anglais</LA>
<EA>Endogenous excitotoxins have been implicated in degeneration of nigral dopaminergic neurons in Parkinson's disease. It may be possible to reduce neurodegeneration by blocking the effects of these endogenous agents. The present study shows that contralateral turning seen following quinolinic acid-induced lesions of the nigrostriatal dopaminergic pathway was reversed by a treatment that increased brain levels of kynurenic acid, an endogenous excitatory amino acid antagonist. The treatment consisted of nicotinylalanine (5.6 nmol/5 μl i.c.v.), an inhibitor of kynureninase and kynurenine hydroxylase plus the precursor kynurenine (450 mg/kg i.p.) plus probenencid (200 mg/kg i.p.), an inhibitor of organic acid transport. Thus, neuroprotection by increasing brain kynurenic acid in vivo may be useful in retarding cell loss in Parkinson's and other neurodegenerative diseases involving excitotoxicity.</EA>
<CC>002B02B10</CC>
<FD>Lésion; Voie nigrostriatale; Comportement rotation; Neuroprotecteur; Parkinson maladie; Animal; Rat; Cynurénique acide</FD>
<FG>Encéphale; Système nerveux central; Rodentia; Mammalia; Vertebrata</FG>
<ED>Lesion; Nigrostriatal pathway; Rotation behavior; Neuroprotective agent; Parkinson disease; Animal; Rat</ED>
<EG>Brain (vertebrata); Central nervous system; Rodentia; Mammalia; Vertebrata</EG>
<SD>Lesión; Vía nigroestriatal; Comportamiento rotación; Neuroprotector; Parkinson enfermedad; Animal; Rata</SD>
<LO>INIST-17240.354000074775170030</LO>
<ID>99-0210506</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D74 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000D74 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:99-0210506
   |texte=   Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus

Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri